A single blood draw added to routine cancer screenings found roughly seven times more cancers than standard tests alone, according to results from the PATHFINDER 2 trial now circulating in corporate and regulatory filings. The study, sponsored by GRAIL and registered on ClinicalTrials.gov as NCT05155605, tested the company’s Galleri multi-cancer early detection (MCED) blood test in a screening population already eligible for U.S. Preventive Services Task Force (USPSTF) grade A and B recommended screenings such as mammography, low-dose CT for lung cancer, and colonoscopy. The size of that detection gap, and the questions it leaves open about what happens after a positive result, now sit at the center of a debate over whether health systems should fold blood-based cancer tests into everyday clinical practice.
Why the PATHFINDER 2 detection gap demands scrutiny now
Standard USPSTF-recommended screenings cover only five cancer types: breast, cervical, colorectal, lung, and prostate. The remaining cancers, which account for the majority of cancer deaths in the United States, have no approved population-level screening test. That gap is what MCED blood tests aim to fill, and the PATHFINDER 2 results represent a striking quantitative argument for adding one to the clinical toolkit.
According to a GRAIL investor presentation, the Galleri test detected 6.5 times more cancers when layered on top of USPSTF A/B screenings. A separate GRAIL press statement described the increase as “more than seven-fold.” The difference between those two framings, 6.5x versus more than seven-fold, reflects how the same dataset can be presented with different rounding conventions, and readers should treat both as company-reported figures rather than independently adjudicated findings.
One hypothesis worth testing against the data is that sites where patients already had high compliance with recommended screenings likely saw a smaller bump from the MCED test than sites where baseline screening rates were low. If PATHFINDER 2 enrollment zip codes were cross-referenced with county-level screening adherence data from national surveillance systems, researchers could measure whether the blood test’s added value tracks inversely with existing screening uptake. That analysis has not been published, but it would help policymakers decide where to deploy the test first for maximum impact, and whether it should be prioritized in regions where conventional screenings are underused.
What the PATHFINDER studies measured and what they found
The original PATHFINDER study, a prospective cohort trial preceding PATHFINDER 2, was published in a Lancet article and established that implementing the methylation-based blood test in real-world clinics was feasible. That earlier trial tracked diagnostic workup pathways after a positive signal and reported low rates of invasive follow-up procedures, a critical safety metric for any screening tool applied to large, mostly healthy populations. Clinicians were able to integrate the test into routine visits, communicate results, and coordinate downstream imaging and biopsies without overwhelming local systems.
PATHFINDER 2 built on that foundation with a larger intended-use screening population and refined performance endpoints more closely aligned with a potential commercial indication. The SEC-filed investor deck reported that fewer than 1% of participants underwent invasive diagnostic procedures after a positive test, and a high proportion of diagnostic evaluations were non-invasive, according to GRAIL. Those numbers matter because the chief risk of any new screening test is not the blood draw itself but the cascade of imaging, biopsies, and surgeries that follow a positive result, many of which turn out to be false alarms. Keeping invasive procedures below the 1% threshold suggests that, at least in the controlled environment of a trial, clinicians exercised restraint rather than reflexively escalating to surgery.
The National Cancer Institute has clarified that MCED tests are not stand-alone screens. A positive result triggers follow-up procedures such as mammography, low-dose CT, colonoscopy, or Pap testing, depending on the cancer signal origin the test identifies. That distinction is important: the blood test does not replace existing screenings but rather adds a layer that catches cancers those screenings miss entirely. In practice, that means a patient might have a normal mammogram and colonoscopy yet still be flagged by the blood test for an otherwise unscreened cancer type, such as pancreatic or ovarian cancer, and then be directed to targeted imaging.
In both PATHFINDER studies, the workflow after a positive result followed a structured algorithm: confirm the signal origin suggested by the test, order imaging focused on that anatomical region, and escalate to biopsy only if imaging raised sufficient concern. This stepwise approach is designed to limit unnecessary interventions while still acting quickly on credible cancer signals. The reported low rates of invasive follow-up imply that, within the trial, most participants with positive tests either had their cancer confirmed through non-invasive means or were ultimately found not to have cancer without undergoing surgery or other high-risk procedures.
Missing data on stage shift, survival, and per-cancer accuracy
The strongest claim any screening test can make is that it saves lives by catching cancer at an earlier, more treatable stage. PATHFINDER 2 has not yet delivered that evidence. The trial’s ClinicalTrials.gov registry entry describes endpoints focused on test performance and downstream diagnostic workups, not long-term outcomes such as stage shift or overall survival. Without those numbers, the 6.5x detection figure tells us how many more cancers the test found, not whether finding them earlier changed patient outcomes.
Detailed per-cancer sensitivity and specificity tables are also absent from the publicly available SEC filing. Sensitivity, the test’s ability to catch a cancer that is actually present, can vary widely across cancer types. A test that reliably detects pancreatic cancer at stage one would be far more valuable than one that mostly picks up slow-growing thyroid cancers that might never become lethal. Without granular breakdowns, clinicians cannot fully assess which patients benefit most or whether certain tumor types are being overrepresented among the positives.
The same uncertainty applies to specificity, the ability to correctly identify people who do not have cancer. Even a small drop in specificity, when applied to millions of screened individuals, can translate into large numbers of false positives. PATHFINDER 2’s low rate of invasive follow-up suggests that many false positives, if they occurred, were resolved with imaging and observation rather than surgery. Still, health systems will want to see independent estimates of false-positive rates by age group and comorbidity burden to understand how the test behaves outside a trial setting.
Stage distribution at diagnosis is another critical gap. If most cancers detected by Galleri in PATHFINDER 2 were already at advanced stages, the clinical value of earlier detection would be limited. Conversely, a shift toward stage I and II diagnoses, particularly for lethal cancers that currently present late, would strengthen the argument for broad adoption. Absent published stage data, policymakers are left to infer potential benefit from detection counts alone, a weak basis for coverage and reimbursement decisions.
How policymakers and clinicians might use PATHFINDER 2
Despite these uncertainties, the PATHFINDER 2 results are already shaping conversations about how to integrate MCED tests into preventive care. One near-term use case is targeted deployment in high-risk populations who either do not qualify for existing USPSTF screenings or struggle to complete them. For example, older adults with multiple comorbidities may be poor candidates for colonoscopy but could still undergo a blood draw, with positive results guiding selective imaging rather than blanket invasive procedures.
Health systems could also pilot MCED testing in regions where adherence to standard screenings is low, using the blood test as both a catch-up tool and a way to re-engage patients with preventive care. However, such strategies should be accompanied by rigorous data collection on follow-up patterns, patient anxiety, and incidental findings to ensure that the promise of earlier detection does not come at the cost of overdiagnosis and overtreatment.
For regulators and payers, the PATHFINDER 2 detection gap is both intriguing and incomplete. The trial shows that adding a single blood test to existing screenings can uncover substantially more cancers with relatively few invasive follow-ups. Yet it does not answer the decisive questions about survival benefit, quality of life, or cost-effectiveness across diverse health systems. Until those data emerge, MCED tests like Galleri are likely to occupy a liminal space: technically feasible, clinically promising, but not yet fully endorsed as standard of care.
In that context, the most prudent path forward may be controlled implementation within learning health systems, where every test is coupled to structured outcome tracking. Such an approach would allow clinicians to offer MCED testing to patients who value the possibility of earlier detection while generating the real-world evidence needed to determine whether the impressive detection gap observed in PATHFINDER 2 ultimately translates into fewer advanced cancers and more lives saved.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
